Literature DB >> 19345233

JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition.

Ruggero Galici1, Jamin D Boggs, Leah Aluisio, Ian C Fraser, Pascal Bonaventure, Brian Lord, Timothy W Lovenberg.   

Abstract

Histamine 3 (H(3)) receptors are distributed throughout the brain and regulate histamine as well as the activity of other neurotransmitters including acetylcholine (ACh). Impaired ACh neurotransmission is associated with deficits of cognitive-related functioning in many species including humans. The goal of these studies was to evaluate the behavioral and neurochemical effects of JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, in rats. The pharmacokinetic profile and receptor occupancy of JNJ-10181457 were tested. The efficacy of JNJ-10181457 was evaluated, acutely, in the imetit-induced water licking model, delayed non-matching to position (DNMTP) task and microdialysis studies. In addition, the effects of repeated administration of JNJ-10181457 were evaluated in the reversal learning task. A single administration of JNJ-10181457 (10 mg/kg, i.p.) resulted in significant plasma and brain exposure and maximal H(3) receptor occupancy. In addition, JNJ-10181457 reversed imetit-induced water licking, similarly to thioperamide (10 mg/kg, i.p.). In the DNMTP task, scopolamine (0.06 mg/kg, i.p.) significantly decreased percentage correct responding. These effects were significantly reversed by JNJ-10181457 (10 mg/kg, i.p.) and also by donepezil (1 mg/kg, i.p.), an acetylcholinesterase inhibitor, and were associated with normalization of ACh neurotransmission in the cortex. Repeated administration of JNJ-10181457 (10 mg/kg, i.p.) significantly increased percentage correct responding in the reversal learning task. Treatment discontinuation was not associated with rebound effects on cognition. These results indicate that selective blockade of histamine H(3) receptors might have therapeutic utility for the treatment of working memory deficits and learning disorders, especially those in which ACh neurotransmission is compromised.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19345233     DOI: 10.1016/j.neuropharm.2009.03.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  20 in total

1.  Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease.

Authors:  Mark E Bardgett; Natasha N Davis; Patrick J Schultheis; Molly S Griffith
Journal:  Neurobiol Learn Mem       Date:  2010-11-10       Impact factor: 2.877

Review 2.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

3.  The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats.

Authors:  Mark E Bardgett; Megan Points; Jennifer Kleier; Meredith Blankenship; Molly S Griffith
Journal:  Neuropharmacology       Date:  2010-07-16       Impact factor: 5.250

4.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

5.  JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats.

Authors:  Ruggero Galici; Amir H Rezvani; Leah Aluisio; Brian Lord; Edward D Levin; Ian Fraser; Jamin Boggs; Natalie Welty; James R Shoblock; S Timothy Motley; Michael A Letavic; Nicholas I Carruthers; Christine Dugovic; Timothy W Lovenberg; Pascal Bonaventure
Journal:  Psychopharmacology (Berl)       Date:  2010-11-18       Impact factor: 4.530

6.  Differential effects of the histamine H(3) receptor agonist methimepip on dentate granule cell excitability, paired-pulse plasticity and long-term potentiation in prenatal alcohol-exposed rats.

Authors:  Rafael K Varaschin; Martina J Rosenberg; Derek A Hamilton; Daniel D Savage
Journal:  Alcohol Clin Exp Res       Date:  2014-05-12       Impact factor: 3.455

7.  Histamine is required for H₃ receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation.

Authors:  J Vanhanen; S Nuutinen; M Lintunen; T Mäki; J Rämö; K Karlstedt; P Panula
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

8.  Single dose of H3 receptor antagonist--ciproxifan--abolishes negative effects of chronic stress on cognitive processes in rats.

Authors:  Emil Trofimiuk; Jan J Braszko
Journal:  Psychopharmacology (Berl)       Date:  2013-08-24       Impact factor: 4.530

Review 9.  The histaminergic network in the brain: basic organization and role in disease.

Authors:  Pertti Panula; Saara Nuutinen
Journal:  Nat Rev Neurosci       Date:  2013-07       Impact factor: 34.870

Review 10.  Monoaminergic neuropathology in Alzheimer's disease.

Authors:  Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.